Abstract:This study systematically organized the discovery of antibodies into three stages and analyzed the advantages and disadvantages of each stage. Meanwhile, This study deeply analyzes challenges, proposing innovative strategies for the next generation of diagnostic antibody development. Aimed at moving closer to the gold standard of antibody discovery, these strategies enhance the competitiveness of diagnostic reagent products. Over the past century, the field of antibody discovery has undergone significant evolution, excluding the current exploration stage of artificial intelligence‐based antibody generation and the often overlooked non‐animal sourced antibody discovery, which typically requires mature in vitro affinity and the selection of high‐quality antigen formulations. This journey has traversed various stages, from methods involving serum‐based antibody acquisition, the isolation of B cells capable of perpetual antibody production through hybridoma technology, to the in‐depth exploration of genetic material using the phage display system, and the current stage involving diverse single B cell screening techniques. Additionally, the emergence of machine learning has brought impressive scientific and technological breakthroughs across research domains, proving to be a powerful application in the field of antibody discovery. However, each technique comes with its limitations, such as variability and control challenges in serum‐based acquisition, lengthy and difficult hybridoma‐derived antibody development, potential limitations in sequence and epitope diversity due to immunization biases in phage display techniques, and costly single B cell screening. Protein mass spectrometry sequencing, with shorter acquisition time and lower costs, is seen as a shortcut by diagnostic companies, impacting traditional antibody development. In diagnostic antibody development, methodological differences in downstream assays and the impact of constant regions outside the Fv core are often neglected. This paper deeply analyzes challenges, proposing innovative strategies for the next generation of diagnostic antibody development. Aimed at moving closer to the gold standard of antibody discovery, these strategies enhance the competitiveness of diagnostic reagent products.

Best practices for machine learning in antibody discovery and development

Best practices for machine learning in antibody discovery and development

Accelerating antibody discovery and design with artificial intelligence: recent advances and prospects

Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery

Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space

Monoclonal antibodies: technologies for early discovery and engineering

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Antibody DomainBed: Out-of-Distribution Generalization in Therapeutic Protein Design

Development and use of machine learning algorithms in vaccine target selection

Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries

Antibody Representation Learning for Drug Discovery

Advancing Antibody Engineering through Synthetic Evolution and Machine Learning

In Silico Approaches to Deliver Better Antibodies by Design: The Past, the Present and the Future

Sequence-based deep learning antibody design for in silico antibody affinity maturation

A new era of antibody discovery: an in-depth review of AI-driven approaches

The challenges and breakthroughs in the development of diagnostic monoclonal antibodies

Machine learning for antimicrobial peptide identification and design

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

Meta learning addresses noisy and under-labeled data in machine learning-guided antibody engineering